Citius Pharmaceuticals Inc – NASDAQ:CTXRW

Citius Pharmaceuticals stock price today

$0.144

Citius Pharmaceuticals stock price monthly change

+10.77%
month

Citius Pharmaceuticals stock price quarterly change

-43.53%
quarter

Citius Pharmaceuticals stock price yearly change

-82.86%
year

Citius Pharmaceuticals key metrics

Market Cap
N/A
Enterprise value
N/A
P/E
-0.68
EV/Sales
N/A
EV/EBITDA
0.86
Price/Sales
N/A
Price/Book
0.19
PEG ratio
0.02
EPS
-0.68
Revenue
N/A
EBITDA
-30.39M
Income
-30.69M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Citius Pharmaceuticals stock price history

Citius Pharmaceuticals stock forecast

Citius Pharmaceuticals financial statements

Citius Pharmaceuticals Inc (NASDAQ:CTXRW): Profit margin
Sep 2021 0 -4.96M
Dec 2021 0 -9.22M
Mar 2022 0 -7.59M
Jun 2022 0 -8.91M
Citius Pharmaceuticals Inc (NASDAQ:CTXRW): Debt to assets
Sep 2021 142429059 9.64M 6.77%
Dec 2021 137516076 12.95M 9.42%
Mar 2022 127785970 9.59M 7.5%
Jun 2022 120315795 9.97M 8.29%
Citius Pharmaceuticals Inc (NASDAQ:CTXRW): Cash Flow
Sep 2021 -5.59M -40M -120.47M
Dec 2021 -4.65M 0 95.88K
Mar 2022 -9.66M 0 0
Jun 2022 -7.71M 0 178K

Citius Pharmaceuticals other data

Citius Pharmaceuticals Inc (NASDAQ:CTXRW): Insider trades (number of shares)
Period Buy Sel
Apr 2019 2588996 0
Sep 2019 5586594 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 2,234,700 $3.45 $7,709,715
Purchase
MAZUR LEONARD L director, 10 perc.. Warrant to Purchase Common Stock 2,234,700 $3.45 $7,709,715
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 558,597 $1.15 $642,387
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Warrant to Purchase Common Stock 558,597 $1.15 $642,387
Purchase
MAZUR LEONARD L director, 10 perc.. Warrant to Purchase Common Stock 1,165,048 $3.45 $4,019,416
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 1,165,048 $3.45 $4,019,416
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Warrant to Purchase Common Stock 129,450 $1.15 $148,868
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 129,450 $1.15 $148,868
Purchase
MAZUR LEONARD L director, 10 perc.. Common Stock 3,137,255 $3.45 $10,823,530
Purchase
HOLUBIAK MYRON Z director, 10 perc.. Common Stock 784,314 $1.15 $901,961
  • What's the price of Citius Pharmaceuticals stock today?

    One share of Citius Pharmaceuticals stock can currently be purchased for approximately $0.14.

  • When is Citius Pharmaceuticals's next earnings date?

    Unfortunately, Citius Pharmaceuticals's (CTXRW) next earnings date is currently unknown.

  • Does Citius Pharmaceuticals pay dividends?

    No, Citius Pharmaceuticals does not pay dividends.

  • What is Citius Pharmaceuticals's stock symbol?

    Citius Pharmaceuticals Inc is traded on the NASDAQ under the ticker symbol "CTXRW".

  • What is Citius Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Citius Pharmaceuticals?

    Shares of Citius Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • When Citius Pharmaceuticals went public?

    Citius Pharmaceuticals Inc is publicly traded company for more then 8 years since IPO on 3 Aug 2017.

Citius Pharmaceuticals company profile:

Citius Pharmaceuticals Inc

Exchange:

NASDAQ

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.


,

CIK: 0001506251
:
: